Journal reading: Tamoxifen Increases risk of complications for micro breast reconstruction (is estrogen some kind of magic healing hormone?)

Posted on February 18, 2012

I like to read my journals.  The Feb 2012 issue of Plastic and Reconstructive Surgery Journal had an article “Tamoixfen Increases the Risk of Microvascular Flap Complications in Patients Undergoing Microvascular Breast Reconstruction.”  Long title.  In English:

The question:  Should they?  Should they be stopping Tamoxifen?  Is Tamoxifen associated with higher complication rates?

So, the study out of Houston.  They looked at 670 patients who underwent delayed reconstruction (immediate recon would not be on Tamoxifen yet).  Rates of microvascular flap (TRAM is the most common) complications and pulmonary emboli rates were looked at.

Results:

They conclude Tamoxifen should be stopped 28 days prior to surgery.  I found this article interesting, in that it dovetails some of the theories in another paper which I blogged about recently which discussed how postmenopausal women have higher breast reduction complications.  Is estrogen some kind of magic healing hormone?  We can’t blindly take lots of estrogen due to its association with making estrogen responsive breast tumors grow faster.  But we are starting to evaluate estrogen.  It is thought estrogen receptors on the vascular endothelium (lining of arteries and veins) increase blood flow.

They concluded their article by stating it is unclear how long you need to be off Tamoxifen before surgery.